OnkologieView membership options
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
VIP articleLancet Oncol — DeWeese TL, Manzanera A, Sylvester J
ME
MedScopeGlobal Editorial
May 31, 2026
OnkologieVIP
Evidence-based clinical briefing
Aglatimagene besadenovec (CAN-2409) with
MedScope VIP
This article is reserved for VIP subscribers. Upgrade for full access, an ad-free reading experience, and priority clinical alerts.
Doporučený obsah
Články
- Mapping the intellectual structure and emerging trends of neurophobia research in health professions education
- Mapping the intellectual structure and emerging trends of neurophobia research in health professions education
- Synergistic Renoprotective Effects of Moderate-Intensity Resistance Training and Vitamin D Supplementation on a Type 2 Diabetic Nephropathy Rat Model
- Diagnostika a screening u nejčastějších symptomů
Studie
- RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings
- Upskilling Rheumatology Occupational Therapists in Work Rehabilitation: An Evaluation of a Job Retention Vocational Rehabilitation Training Course (the Workwell Trial)
- Satisfaction with telemedicine versus in-person visits in rheumatology: a noninferiority randomised controlled trial